Maor Epstein

Mr. Maor Epstein

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
OBOrtal Buhbut
Ortal Buhbut
HAHadas Ben Assayag
Hadas Ben Assayag
SBSapir Aharoni- Bar
Sapir Aharoni- Bar
MEMaor Epstein
Maor Epstein
ETErez Tsumi
Erez Tsumi
Anat HorevAnat Horev
Anat Horev
Objective: Patients with chronic idiopathic intracranial hypertension (IIH) commonly experience a high level of disability and low satisfaction with medical treatment. We aim to evaluate long-term functional improvement and patient satisfaction in IIH patients with similar symptoms by comparing venous sinus stenting (VSS) to standard medical therapy. Methods: We conducted a cross-sectional questionnaire study of 111 IIH patients, comparing 37 adult female patients who underwent venous sinus stenting with 74 patients treated medically. Propensity score matching was used to balance age and presence of papilledema at presentation between groups. Headache-related disability was evaluated using the Migraine Disability Assessment Scale (MIDAS), while general function and treatment satisfaction were assessed using custom questionnaires. Electronic medical records and the results of imaging upon diagnosis were reviewed retrospectively. Results: The stented group reported significantly better outcomes in physical well-being (median 4.0 vs. 1.0, p < 0.001), task completion (4.0 vs. 1.0, p < 0.001), work/school persistence (5.0 vs. 1.0, p < 0.001), and mental well-being (4.0 vs. 1.0, p < 0.001). Additionally, the stented group had a lower proportion of patients with severe MIDAS (MIDAS > 4, 24.3% vs. 47.9%, p = 0.017). Logistic regression suggested venous stenting as a protective factor against severe MIDAS scores (OR = 0.174, p = 0.004). Conclusion: Cerebral venous stenting in patients with IIH is associated with lower disability and higher patient satisfaction from medical treatment compared to those treated with medications only. These findings suggest that venous sinus stenting may be a valuable treatment option for selected IIH patients. However, larger prospective studies are needed to further validate our results.

27 April 2025 in OBM Integrative and Complementary Medicine
Verified
Journal Article
Open access
PDF file
ZGZohar Gabay
Zohar Gabay
TETal Eliav
Tal Eliav
OHOded Hammerman
Oded Hammerman
OEOdelia Elkana
Odelia Elkana
MEMaor Epstein
Maor Epstein
YEYacov Ezra
Yacov Ezra
Hypnotherapy is effective for treating functional symptoms; however, some studies describe a paradoxical response to hypnotic relaxation. We hypothesized that functional patients who: 1) are aware of a stressful antecedent event and 2) recognize that stress is causing or exacerbating their symptoms would have reduced symptom-severity with hypnotic relaxation, whereas patients who do not perceive a stressful antecedent and do not recognize stress as causing symptoms, would more commonly experience paradoxical response (PR) of increased symptom intensity. In this retrospective analysis, records between 2013-2017 were obtained from the Functional Neurology Clinic (FNC) in Soroka Medical Center, Israel. Patients with functional disorders who underwent a three-session hypnotic relaxation course were included. Ninety patients participated. Patients with low stress awareness exhibited significantly higher PR rates during the first session and throughout the three-session treatment. Specificity of PR as a criterion for lack of insight was 90%. For functional patients who find themselves at an impasse and are resistant to considering psychological etiologies, understanding PR to hypnotic relaxation may serve as a gateway to facilitating psychological treatment.

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IGItamar Gothelf
Itamar Gothelf
MEMaor Epstein
Maor Epstein
ASAdi Shiloh
Adi Shiloh
ZLZachary Lebowitz
Zachary Lebowitz
YZYair Zlotnik
Yair Zlotnik
Anat HorevAnat Horev
Anat Horev
Objective: Stent-assisted treatments for intracranial aneurysms, including stent-assisted coiling (SAC) and flow diversion (FD), are associated with an increased thrombotic risk despite dual antiplatelet therapy (DAPT). Recently, intravenous prophylactic protocols incorporating glycoprotein IIb/IIIa antagonists, adapted from cardiology practices, have been introduced. This study evaluates the safety and efficacy of prophylactic low-dose intra-arterial Eptifibatide for cerebral aneurysm management using SAC or FD. Methods: This single-center, single-arm, retrospective study included 99 patients who underwent endovascular treatment with stent-assisted coiling (SAC) or flow diversion (FD) between 2017 and 2023. All patients were initiated on dual antiplatelet therapy (DAPT) 7 days prior to the procedure. Prophylactic intra-arterial Eptifibatide (2–3 mg) was administered intra-procedurally, immediately after stent deployment. Complications were recorded and categorized as periprocedural (occurring during or within 24 h of the procedure) or postprocedural (occurring between 24 and 72 h after the procedure), and included both thrombotic and hemorrhagic events. Results: Among the 99 patients (mean age 57.0 ± 10.8 years), periprocedural complications included three cases of ischemic-related neurological deficits, with no evidence of stent thrombosis or intracranial branch occlusion. All deficits were resolved within 48 h. An additional two patients developed ischemic-related neurological deficits post-procedural. One patient fully recovered following a short rehabilitation period, while the other was left with mild permanent deficits. Overall, any complications following Eptifibatide administration were observed in 5.1% of patients. No hemorrhagic complications were recorded. Conclusions: Prophylactic low-dose intra-arterial Eptifibatide demonstrated a favorable safety profile, potentially reducing thrombotic complications without substantially increasing hemorrhagic risk.